Omiganan
- Generic Name
- Omiganan
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C90H127N27O12
- CAS Number
- 204248-78-2
- Unique Ingredient Identifier
- 618SLL9VBS
- Background
Omiganan has been investigated for the treatment of Mupirocin-resistant MRSA skin infections.
- Indication
Investigated for use/treatment in bacterial infection and rosacea.
- Associated Conditions
- -
- Associated Therapies
- -
Omiganan Twice a Day (BID) in Patients With Facial Seborrheic Dermatitis
- First Posted Date
- 2018-09-28
- Last Posted Date
- 2019-05-01
- Lead Sponsor
- Maruho Co., Ltd.
- Target Recruit Count
- 36
- Registration Number
- NCT03688971
- Locations
- 🇳🇱
Centre for Human Drug Research, Leiden, Netherlands
Pharmacodynamics of Omiganan BID in Patients With Atopic Dermatitis
- First Posted Date
- 2017-03-27
- Last Posted Date
- 2017-12-27
- Lead Sponsor
- Maruho Co., Ltd.
- Target Recruit Count
- 80
- Registration Number
- NCT03091426
- Locations
- 🇳🇱
LUMC/Centre for Human Drug Research, Leiden, Netherlands
Topical Challenge With Omiganan and Imiquimod in Healthy Volunteers
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2017-03-07
- Last Posted Date
- 2017-05-22
- Lead Sponsor
- Maruho Co., Ltd.
- Target Recruit Count
- 16
- Registration Number
- NCT03071679
- Locations
- 🇳🇱
LUMC/Centre for Human Drug Research, Leiden, Netherlands
Study to Evaluate the Long-term Safety of a Once-Daily Omiganan Topical Gel
- First Posted Date
- 2015-10-15
- Last Posted Date
- 2022-07-19
- Lead Sponsor
- Maruho Co., Ltd.
- Target Recruit Count
- 307
- Registration Number
- NCT02576847
A Twelve Week Safety and Efficacy Study in Rosacea
- First Posted Date
- 2013-02-05
- Last Posted Date
- 2015-05-20
- Lead Sponsor
- Maruho Co., Ltd.
- Target Recruit Count
- 240
- Registration Number
- NCT01784133
- Locations
- 🇺🇸
TriCities Skin and Cancer, Johnson City, Tennessee, United States
🇺🇸ATS Clinical Research, Santa Monica, California, United States
🇺🇸Wake Resarch, Raleigh, North Carolina, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath